PortalPublikationenReduced-Intensity Allografting as First Transplantation Appr...

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

Standard

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. / Klyuchnikov, Evgeny; Bacher, Ulrike; Kröger, Nicolaus-Martin; Hari, Parameswaran N; Ahn, Kwang Woo; Carreras, Jeanette; Bachanova, Veronika; Bashey, Asad; Cohen, Jonathon B; D'Souza, Anita; Freytes, César O; Gale, Robert Peter; Ganguly, Siddhartha; Hertzberg, Mark S; Holmberg, Leona A; Kharfan-Dabaja, Mohamed A; Klein, Andreas; Ku, Grace H; Laport, Ginna G; Lazarus, Hillard M; Miller, Alan M; Mussetti, Alberto; Olsson, Richard F; Slavin, Shimon; Usmani, Saad Z; Vij, Ravi; Wood, William A; Maloney, David G; Sureda, Anna M; Smith, Sonali M; Hamadani, Mehdi.

in: BIOL BLOOD MARROW TR, Jahrgang 21, Nr. 12, 04.08.2015, S. 2091-2099.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klyuchnikov, E, Bacher, U, Kröger, N-M, Hari, PN, Ahn, KW, Carreras, J, Bachanova, V, Bashey, A, Cohen, JB, D'Souza, A, Freytes, CO, Gale, RP, Ganguly, S, Hertzberg, MS, Holmberg, LA, Kharfan-Dabaja, MA, Klein, A, Ku, GH, Laport, GG, Lazarus, HM, Miller, AM, Mussetti, A, Olsson, RF, Slavin, S, Usmani, SZ, Vij, R, Wood, WA, Maloney, DG, Sureda, AM, Smith, SM & Hamadani, M 2015, 'Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors', BIOL BLOOD MARROW TR, Jg. 21, Nr. 12, S. 2091-2099. https://doi.org/10.1016/j.bbmt.2015.07.028

APA

Klyuchnikov, E., Bacher, U., Kröger, N-M., Hari, P. N., Ahn, K. W., Carreras, J., Bachanova, V., Bashey, A., Cohen, J. B., D'Souza, A., Freytes, C. O., Gale, R. P., Ganguly, S., Hertzberg, M. S., Holmberg, L. A., Kharfan-Dabaja, M. A., Klein, A., Ku, G. H., Laport, G. G., ... Hamadani, M. (2015). Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. BIOL BLOOD MARROW TR, 21(12), 2091-2099. https://doi.org/10.1016/j.bbmt.2015.07.028

Vancouver

Klyuchnikov E, Bacher U, Kröger N-M, Hari PN, Ahn KW, Carreras J et al. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. BIOL BLOOD MARROW TR. 2015 Aug 4;21(12):2091-2099. https://doi.org/10.1016/j.bbmt.2015.07.028

Bibtex

@article{89b2b94f872e4edaa2d52086f2503f66,
title = "Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors",
abstract = "This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P < .0001); relapse/progression: 54% versus 20% (P < .0001); progression-free survival (PFS): 41% versus 58% (P < .001), and overall survival (OS): 74% versus 66% (P = .05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P < .0001) and worse PFS (RR, 2.9; P < .0001) beyond 11 months after HCT. In the first 24 months after HCT, auto-HCT was associated with improved OS (RR, .41; P < .0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P = .006). A landmark analysis of patients alive and progression-free at 2 years after HCT confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P < .0001) and inferior PFS (RR, 3.2; P < .0001) and OS (RR, 2.1; P = .04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity-conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.",
author = "Evgeny Klyuchnikov and Ulrike Bacher and Nicolaus-Martin Kr{\"o}ger and Hari, {Parameswaran N} and Ahn, {Kwang Woo} and Jeanette Carreras and Veronika Bachanova and Asad Bashey and Cohen, {Jonathon B} and Anita D'Souza and Freytes, {C{\'e}sar O} and Gale, {Robert Peter} and Siddhartha Ganguly and Hertzberg, {Mark S} and Holmberg, {Leona A} and Kharfan-Dabaja, {Mohamed A} and Andreas Klein and Ku, {Grace H} and Laport, {Ginna G} and Lazarus, {Hillard M} and Miller, {Alan M} and Alberto Mussetti and Olsson, {Richard F} and Shimon Slavin and Usmani, {Saad Z} and Ravi Vij and Wood, {William A} and Maloney, {David G} and Sureda, {Anna M} and Smith, {Sonali M} and Mehdi Hamadani",
note = "Copyright {\textcopyright} 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2015",
month = aug,
day = "4",
doi = "10.1016/j.bbmt.2015.07.028",
language = "English",
volume = "21",
pages = "2091--2099",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

AU - Klyuchnikov, Evgeny

AU - Bacher, Ulrike

AU - Kröger, Nicolaus-Martin

AU - Hari, Parameswaran N

AU - Ahn, Kwang Woo

AU - Carreras, Jeanette

AU - Bachanova, Veronika

AU - Bashey, Asad

AU - Cohen, Jonathon B

AU - D'Souza, Anita

AU - Freytes, César O

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - Hertzberg, Mark S

AU - Holmberg, Leona A

AU - Kharfan-Dabaja, Mohamed A

AU - Klein, Andreas

AU - Ku, Grace H

AU - Laport, Ginna G

AU - Lazarus, Hillard M

AU - Miller, Alan M

AU - Mussetti, Alberto

AU - Olsson, Richard F

AU - Slavin, Shimon

AU - Usmani, Saad Z

AU - Vij, Ravi

AU - Wood, William A

AU - Maloney, David G

AU - Sureda, Anna M

AU - Smith, Sonali M

AU - Hamadani, Mehdi

N1 - Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2015/8/4

Y1 - 2015/8/4

N2 - This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P < .0001); relapse/progression: 54% versus 20% (P < .0001); progression-free survival (PFS): 41% versus 58% (P < .001), and overall survival (OS): 74% versus 66% (P = .05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P < .0001) and worse PFS (RR, 2.9; P < .0001) beyond 11 months after HCT. In the first 24 months after HCT, auto-HCT was associated with improved OS (RR, .41; P < .0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P = .006). A landmark analysis of patients alive and progression-free at 2 years after HCT confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P < .0001) and inferior PFS (RR, 3.2; P < .0001) and OS (RR, 2.1; P = .04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity-conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.

AB - This study was conducted to compare long-term outcomes in patients with refractory/relapsed grades 1 and 2 follicular lymphoma (FL) after allogeneic (allo) versus autologous (auto) hematopoietic cell transplantation (HCT) in the rituximab era. Adult patients with relapsed/refractory grades 1 and 2 FL undergoing first reduced-intensity allo-HCT or first autograft during 2000 to 2012 were evaluated. A total of 518 rituximab-treated patients were included. Allo-HCT patients were younger and more heavily pretreated, and more patients had advanced stage and chemoresistant disease. The 5-year adjusted probabilities, comparing auto-HCT versus allo-HCT groups for nonrelapse mortality (NRM) were 5% versus 26% (P < .0001); relapse/progression: 54% versus 20% (P < .0001); progression-free survival (PFS): 41% versus 58% (P < .001), and overall survival (OS): 74% versus 66% (P = .05). Auto-HCT was associated with a higher risk of relapse/progression beyond 5 months after HCT (relative risk [RR], 4.4; P < .0001) and worse PFS (RR, 2.9; P < .0001) beyond 11 months after HCT. In the first 24 months after HCT, auto-HCT was associated with improved OS (RR, .41; P < .0001), but beyond 24 months, it was associated with inferior OS (RR, 2.2; P = .006). A landmark analysis of patients alive and progression-free at 2 years after HCT confirmed these observations, showing no difference in further NRM between both groups, but there was significantly higher risk of relapse/progression (RR, 7.3; P < .0001) and inferior PFS (RR, 3.2; P < .0001) and OS (RR, 2.1; P = .04) after auto-HCT. The 10-year cumulative incidences of second hematological malignancies after allo-HCT and auto-HCT were 0% and 7%, respectively. Auto-HCT and reduced-intensity-conditioned allo-HCT as first transplantation approach can provide durable disease control in grades 1 and 2 FL patients. Continued disease relapse risk after auto-HCT translates into improved PFS and OS after allo-HCT in long-term survivors.

U2 - 10.1016/j.bbmt.2015.07.028

DO - 10.1016/j.bbmt.2015.07.028

M3 - SCORING: Journal article

C2 - 26253007

VL - 21

SP - 2091

EP - 2099

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 12

ER -